ArticleMolecular diversity2026
Synthesis and biological evaluation of Phorbazole D analogues identify IO-5a as a promoter of hUC-MSC chondrogenic differentiation.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Mesenchymal stem cells (MSCs) are a promising cell source for osteoarthritis and intervertebral disc degeneration, but their application is limited by inefficient and unstable chondrogenic differentiation. Here, nine Phorbazole D analogues were synthesized and evaluated for promoting chondrogenesis in human umbilical cord mesenchymal stem cells (hUC-MSCs) under TGF-β/dexamethasone based induction conditions. Among the tested analogues, IO-5a was selected for further evaluation based on its comparatively higher pro-chondrogenic activity and no detectable cytotoxicity. Image-based Alcian blue analysis showed that the positive staining area increased from approximately 17% in the control group to approximately 45% after IO-5a treatment. RT-qPCR further showed that 10 µM IO-5a upregulated COL2A1, SOX9, ACAN, and COMP by approximately 2.6-fold, 1.1-fold, 1.35-fold, and 1.4-fold, respectively. Immunofluorescence, western blotting, and 3D pellet culture analyses supported increased cartilage associated marker expression and cartilage like matrix deposition. Preliminary structure-activity relationship analysis suggested that retention of the A-ring phenolic hydroxyl group and favorable A-/C-ring substituent matching may contribute to activity. In silico target prediction and molecular docking nominated PTPN1 (PTP1B) as a potential candidate protein, although this predicted interaction requires further experimental validation. Collectively, IO-5a represents a bioactive Phorbazole D analogue with chondrogenesis promoting activity in hUC-MSCs.
Indexed as
Identifiers
42530800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.